Zoek in de site...

Spin-offs from IMM

The IMM actively stimulates scientists to cross the bridge between science and business. During the past years the IMM has produced many spin-off companies. Synthon is the largest and oldest spin-off, with a worldwide headcount of 1600 people.

Cytofind Diagnostics
Circulating tumour cells (CTCs) are shed from tumours and circulate in the naamloosblood, They are the seeds of secondary tumours and may provide a wealth of information on metastatic mechanisms, disease progression and treatment susceptibility. The quantification and analysis of these cells (taken from a patient's blood sample) thus holds great promise to improve the treatment of metastatic cancer. Cytofind Diagnostics aims to bring to market a proprietary CTC detection method based on a combination of a highly innovative picodroplet-based microfluidic technology for single cell analysis, and the metabolic characteristics of tumour cells.

ProtInhi
Develops novel drugs against diseases wit high umet medical protinhi-logoneed using proprietary technology and compoundsthat target diseases via Protease Inhibition. The focus of ProtInhi is on upcoming viral threats and particularly on Dengue.

GATT Technologies
The global market for hemostats and sealants is an attractive 4B$ market, Gattgrowing with 5-10% per year. Many products are offered by many vendors, but the market is still lacking products to address the unmet needs of: controlling severe bleedings (@competitive price levels) and preventing leakage in high demanding sealant applications. Triggered by this strong market need and the idea for a new technology, GATT Technologies BV was founded in 2011 by Johan Bender, with the ambition to develop a superior synthetic surgical hemostat and sealant platform to enable the bundling of all desirable features in medical device products. Driven by this needs, the actual market is shifting from expensive fibrin based medicines to more effective, easier to use, synthetic NHS-based medical device solutions.

Synaffix  
Focused on continued advancement of our best-in-class antibody-drug Synaffix-LogoRGBconjugate (ADC) technology platform.  As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure.

NovioSense  
A spin out company from Fraunhofer IMS in Duisburg, NovioTech b.v. and RadNovioSense nov15boud University. The NovioSense technology is a wireless platform for non-invasive monitoring of disease biomarkers in tear fluids.

Secmatix
This biomaterials company is a joint collaboration between the Molecular Materials Group and the Radboud UMC. The company was founded to commercialize the Nijmegen 'super gel' and is developing new adaptive wound dressings, biogels for drug delivery and regenerative medicine platforms.

Solar SwingSolarSwing
Development and production of daylight regulation systems that at the same time generate energy by smart integration of high-efficiency photovoltaic cells.

NovioTech
A fully privately held corporation committed to bringing new technological solutions to the market. NovioTech collaborates with Radboud University to valorize a number of technologies developed in the organic chemistry cluster of IMM.

ReRa Solutions
In 2016, the new start-up company ReRa Monitoring, which evolved from John Schermer’s solar cell group (Applied Materials Science), will test its highly accurate solar performance system for the first time in practice at pilot customer Zonnepark Nijmegen (owned by ENGIE, formerly GDF Suez). ReRa Monitoring will use the funding acquired from Power2Nijmegen and the Mercator Incubator Fund.

Sphere Fluidics
With novel analytical instrumentation and collaborative research services sphereSphere Fluidics enables the rapid screening and characterisation of single cells and their biological products for use in research, biotherapeutic discovery, bioproduction, cell therapy engineering, drug discovery and diagnostics.

TF2 Devices  
Development and production of thin-film III-V devices based on the epit150tf2axial lift-off (ELO) technique. This technique brings numerous advantages to a whole range of (opto)electronic devices.

FutureChemistry
Offers lab-on-a-chip technology for chemical and pharmaceutical futureChemistry-logoapplications. FutureChemistry develops, implements and sells microreactor hardware and procedures for optimising and screening chemical reactions and processes. It develops its products from the customer’s perspective and has in-house expertise for that.

Encapson
Performs custom synthesis of functional polymers and encapsondevelops encapsulation technology vased on block co-polymers.

ModiQuest
Develops and commercializes novel proprietary therapeutic and diagnostic antibodies. ModiQuest applies innovative technologies including differential proteomics in the identification of disease related protein modifications. It uses automated high-throughput B-cell selection, highly efficient electrofusion methods, and recombinant antibody technology for the generation of corresponding diagnostic and/or therapeutic monoclonal antibodies.

Sensor Sense sensorsense
An innovative company specialized in the development and commercialization of highly sensitive and selective laser-based gas detectors for scientific and industrial applications. Furthermore, we offer peripheral equipment indispensable to perform successful trace gas analysis.

Spinnovation  
Specialised in performing contract research and supplying contract analysis Spinnovationservices to support the Pharma, Food, Chemical & Polymer industries. Spinnovation provides access to a unique combination of applied analytical science expertise, with state-of-the-art technology and innovative approaches. In addition to NMR methods and techniques, Spinnovation offers services based on hyphenated technologies such as LC-MS, LC-NMR, LC-SPE-NMR, LC-SPE-NMR-MS. Spinnovation can perform analyses of molecules either in isolated form or in complex mixtures.

Chiralix 
Focusses on the development and supply of chiral 'drug-like' chiralixbuilding blocks on research-scale for drug discovery and early development.

Syntarga 
Develops releasable linker technologies and products for site-specific and efficient targeted drug release. Aquired by Synthon in 2011.

Mercachem 
Provides high-quality chemistry services for clients who require a small-molecule solution. Currently, Mercachem mercachemblauwemploys approximately 150 people in Nijmegen (NL) and Prague (CZ).

Synthon 
Produces pharmaceuticals and is by far the largest spin-off company of the IMM, Synthonnow employing over 1250 people worldwide. Synthon is committed to delivering affordable medicines through innovative science. The strategic steps that were taken over the last 20 years have successfully positioned the company as they moved towards achieving the goal of becoming a fully-fledged specialty pharmaceuticals provider.